$BMBIF News

Last published 4y ago

4y agoBMBIF DRUGBright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development OrganizationGlobeNewswireVANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsyc
4y agoBMBIF DRUGBright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet SyndromeGlobeNewswire-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company"
4y agoBMBIF DRUGBright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health SpecialtiesGlobeNewswire-- Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of clinical and research expertise in psychiatry, addiction, behavioral health, and pharmacology to guide
4y agoBMBIF DRUGBright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion LeadersGlobeNewswire-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or
4y agoBMBIF DRUGBright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical TrialGlobeNewswireVANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsy
4y agoBMBIF DRUGBright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare ConferenceGlobeNewswireVANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsy
4y agoBMBIF DRUGBright Minds Biosciences to Present at the H.C. Wainwright Bioconnect ConferenceGlobeNewswireVANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsyc
4y agoBMBIF DRUGBright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare ConferenceGlobeNewswireVANCOUVER, British Columbia, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsyc
4y agoBMBIF DRUGBright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental DiseasesGlobeNewswire— Hundreds of de novo patentable psychedelic-based compounds created through discovery program — — Company plans to announce lead molecule in first quarter of 2022 — VANCOUVER, British Columbia, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Brigh
5y agoBMBIF DRUGBright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol "DRUG"GlobeNewswireVANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiat
5y agoAWKNF BETRF BMBIF CYBN+16KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand ViewingPR NewswireNEW YORK, Oct. 18, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.
5y agoAWKNF BETRF BMBIF CYBN+13KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14thPR NewswireNEW YORK, Oct. 11, 2021 /PRNewswire/ -- Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional inves
5y agoBMBIFBright Minds Biosciences Inc. to Webcast Live At VirtualInvestorConferences.com October 14thPR NewswireNEW YORK, Oct. 7, 2021 /PRNewswire/ -- BRIGHT MINDS BIOSCIENCES INC. (CSE:DRUG), based in New York focused on new approaches to neuroscience, today announced that Ian McDonald, President & CEO and Josh Blacher, VP of Corporation Development, will presen
5y agoBMBIFBright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment ConferenceGlobeNewswireVANCOUVER, British Columbia, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiat
5y agoBMBIFBright Minds Biosciences Provides Scientific UpdateGlobeNewswireVANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychia
5y agoBMBIFBright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC ClearanceGlobeNewswireVANCOUVER, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychia
5y agoBMBIFBright Minds Biosciences ("BMB") Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure ActivityGlobeNewswire-- BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency -- -- Effect of BMB compounds was consistent with other anti-epileptics such as fenfluramine
5y agoBMBIFBright Minds Biosciences Announces Application to List on NasdaqGlobeNewswireVANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry
5y agoBMBIFBright Minds Biosciences Appoints New Board Member and Expands Leadership TeamGlobeNewswireVANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry
5y agoBMBIFBright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and BeyondGlobeNewswireVANCOUVER, British Columbia, June 11, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry
5y agoBMBIFBright Minds Biosciences to Present at the 2021 LD Micro Invitational XIGlobeNewswireVANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry
5y agoBMBIFBright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021GlobeNewswireVANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry